About the Company
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRTA News
Prothena Plc (NASDAQ: PRTA)
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical ...
Prothena Corp PLC PRTA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript
Prothena Corporation plc misses on earnings expectations. Reported EPS is $-1.26 EPS, expectations were $-1.23. PRTA isn't one of the 30 most popular stocks among hedge funds at the end of the ...
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
It had no debt as of the same date. Prothena Corporation plc Price, Consensus and EPS Surprise Revenues in 2023 totaled $91.4 million, up from $53.9 million in 2022. The figure, however ...
Prothena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 Outlook
Warning! GuruFocus has detected 3 Warning Signs with PRTA. On February 15, 2024, Prothena Corp PLC (NASDAQ:PRTA) released its 8-K filing, detailing the financial results for the fourth quarter and ...
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Prothena Corporation plc (NASDAQ:PRTA) is gearing up to report an update on its ongoing phase 1 study, using PRX012 for the treatment of patients with Alzheimer's Disease [AD]. It is expected that ...
Prothena Corp PLC PRTA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript
Gene Kinney : Yeah, maybe – thank you for the question and maybe I can just take this one. I think, what we’re looking for is to really have a fulsome understanding of the exposure response ...
Prothena Corporation plc
Not all exchange-traded funds are created equal. These five-star funds are some of the cream of the ETF crop. Investing can help you reach the $1 million mark if you start early, stay in the ...
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript
We appreciate your interest in Prothena and we look very much forward to sharing further updates on our program. Have a good afternoon. Operator: Thank you for participating in today’s ...
Loading the latest forecasts...